nach oben

International Urology and Nephrology

Erschienen in:

01.03.2015 | Nephrology – Original Paper

Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis

verfasst von: Chun-Juan Zhai, Xiao-Wei Yang, Jing Sun, Rong Wang

Erschienen in: International Urology and Nephrology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We conducted this review to assess the relative efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in chronic kidney disease.

Methods

We systematically searched PubMed, EMBASE, the Cochrane Controlled Trial Register of Controlled Trials and Chinese Biological Medical Database for randomized controlled trials comparing lanthanum carbonate with calcium-based phosphate binders in adult patients with chronic kidney disease. Study quality was assessed using the criteria outlined in the Cochrane Handbook for Systematic Reviews of intervention. Meta-analysis was conducted by reviewer manager software, version 5.3.

Results

Eleven trials with 1,501 participants were included. Lanthanum carbonate appeared to be associated with a significant reduction in progression of vascular calcification and a beneficial effect on bone outcomes without aluminum-like toxicity. Lanthanum carbonate achieved similar proportions of phosphate-controlled patients (RR 0.63, 95 % CI 0.27–1.44) with lower incidence of hypercalcemia (RR 0.13, 95 % CI 0.05–0.35) in comparison with calcium-based phosphate binders. Lanthanum carbonate was associated with significantly lower serum calcium, similar serum Ca × P product and higher serum iPTH compared with calcium salts in patients with chronic kidney disease.

Conclusion

Lanthanum carbonate could delay the progression of vascular calcification and benefit chronic kidney disease patients on bone outcomes. Lanthanum carbonate could achieve similar proportion of phosphate-controlled patients as calcium-based phosphate binders with lower incidence of hypercalcemia.

Nur mit Berechtigung zugänglich

Levey AS, Coresh J (2012) Chronic kidney disease. Lancet 379(9811):165–180. doi:10.1016/S0140-6736(11)60178-5 CrossRefPubMed

Bhan I, Thadhani R (2009) Vascular calcification and ESRD: a hard target. Clin J Am Soc Nephrol 4(Suppl 1):S102–S105. doi:10.2215/CJN.04800709 CrossRefPubMed

Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Disease: Improving Global O (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69(11):1945–1953. doi:10.1038/sj.ki.5000414 CrossRefPubMed

Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol : JASN 15(8):2208–2218. doi:10.1097/01.ASN.0000133041.27682.A2 CrossRefPubMed

Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK (2008) Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52(3):519–530. doi:10.1053/j.ajkd.2008.03.020 CrossRefPubMed

Ohya M, Otani H, Kimura K, Saika Y, Fujii R, Yukawa S, Shigematsu T (2011) Vascular calcification estimated by aortic calcification area index is a significant predictive parameter of cardiovascular mortality in hemodialysis patients. Clin Exp Nephrol 15(6):877–883. doi:10.1007/s10157-011-0517-y CrossRefPubMed

Damment SJ, Pennick M (2008) Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. Clin Pharmacokinet 47(9):553–563CrossRefPubMed

Hutchison AJ, Barnett ME, Krause R, Kwan JT, Siami GA, Group SPDLS (2008) Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract 110(1):c15–c23. doi:10.1159/000149239 CrossRef

Shigematsu T, Lanthanum Carbonate Research G (2008) Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis. Ther Apher Dial 12(1):55–61. doi:10.1111/j.1744-9987.2007.00541.x CrossRefPubMed

10.

Freemont AJ, Hoyland JA, Denton J, SPDSG Lanthanum Carbonate (2005) The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol 64(6):428–437PubMed

11.

Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, Backs W, Jamar R, Vosskuhler A (2005) Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 100(1):c8–c19CrossRefPubMed

12.

Lee YK, Choi HY, Shin SK, Lee HY (2013) Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study. Clin Nephrol 79(2):136–142. doi:10.5414/cn107362 CrossRefPubMed

13.

Ohtake T, Kobayashi S, Oka M, Furuya R, Iwagami M, Tsutsumi D, Mochida Y, Maesato K, Ishioka K, Moriya H, Hidaka S (2013) Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study. J Cardiovasc Pharmacol Ther 18(5):439–446CrossRefPubMed

14.

Scaria PT, Gangadhar R, Pisharody R (2009) Effect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease. Indian J Pharmacol 41(4):187–191. doi:10.4103/0253-7613.56074 CrossRefPubMedCentralPubMed

15.

Shigematsu T, Sakai T, Kono T, Kimura Y, Takuma Y, Tsuruta Y, Mori Y, Taki M, Moriishi M, Minakuchi J, Obayashi S, Miyake S, Emoto H, Furuhashi M, Tsujimoto Y, Arisaka H, Ishizaki M, Shimoyama H, Kim S, Hirose S, Kurosawa A, Matsui N, Nakazawa R, Watanabe T, Kabaya T, Tanaka Y, Takahashi T, Ozawa T, Nakamura K, Nishioka M, Higashi H, Koga N (2008) Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis, patients with hyperphosphatemia. Clin Nephrol 70(5):404–410CrossRefPubMed

16.

Soriano S, Ojeda R, Rodriguez M, Almaden Y, Rodriguez M, Martin-Malo A, Aljama P (2013) The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients. Clin Nephrol 80(1):17–22. doi:10.5414/cn107764 CrossRefPubMed

17.

Spasovski GB, Sikole A, Gelev S, Masin-Spasovska J, Freemont T, Webster I, Gill M, Jones C, De Broe ME, D’Haese PC (2006) Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 21(8):2217–2224. doi:10.1093/ndt/gfl146 CrossRefPubMed

18.

Toida T, Fukudome K, Fujimoto S, Yamada K, Sato Y, Chiyotanda S, Kitamura K (2012) Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study. Clin Nephrol 78(3):216–223CrossRefPubMed

19.

Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG (2011) Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology 16(3):290–298CrossRefPubMed

20.

Wada K, Wada Y (2014) Evaluation of aortic calcification with lanthanum carbonate vs. calcium-based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open-label randomized controlled trial. Ther Apher Dial. doi:10.1111/1744-9987.12153

21.

Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, Lok CE, Fitchett D, Tsuyuki RT (2013) Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 382(9900):1268–1277. doi:10.1016/S0140-6736(13)60897-1 CrossRefPubMed

22.

Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GFM (2009) Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 54(4):619–637

23.

Zhang C, Wen J, Li Z, Fan J (2013) Efficacy and safety of lanthanum carbonate on chronic kidney disease–mineral and bone disorder in dialysis patients: a systematic review. BMC Nephrol 14(1):226. doi:10.1186/1471-2369-14-226 CrossRefPubMedCentralPubMed

24.

Guo H, Zhang X, Tang S, Zhang S (2013) Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis—system review of lanthanum carbonate. Ren Fail 35(10):1455–1464. doi:10.3109/0886022X.2013.828365 CrossRefPubMed

25.

National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(4 Suppl 3):S1–S201

26.

Brennan A, Akehurst R, Davis S, Sakai H, Abbott V (2007) The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease. Value Health 10(1):32–41. doi:10.1111/j.1524-4733.2006.00142.x CrossRefPubMed

27.

Goto S, Komaba H, Moriwaki K, Fujimori A, Shibuya K, Nishioka M, Kim JI, Yoshiya K, Shin J, Hasegawa H, Taniguchi M, Fujii H, Nishi S, Kamae I, Fukagawa M (2011) Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. Clin J Am Soc Nephrol 6(6):1375–1384. doi:10.2215/CJN.08841010 CrossRefPubMedCentralPubMed

28.

Park H, Rascati KL, Keith MS, Hodgkins P, Smyth M, Goldsmith D, Akehurst R (2011) Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective. Value Health 14(8):1002–1009. doi:10.1016/j.jval.2011.05.043 CrossRefPubMed

29.

Vegter S, Tolley K, Keith MS, Postma MJ (2011) Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis. Value Health 14(6):852–858. doi:10.1016/j.jval.2011.05.005 CrossRefPubMed

Titel: Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis
verfasst von: Chun-Juan Zhai
Xiao-Wei Yang
Jing Sun
Rong Wang
Publikationsdatum: 01.03.2015
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 3/2015
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-014-0876-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

The effects of short-term vitamin D supplementation on glucose metabolism in dialysis patients: a systematic review and meta-analysis

Use of the nuclear matrix protein 22 Bladder Chek test™ in the diagnosis of residual urothelial cancer before a second transurethral resection of bladder cancer

Tissue advanced glycation end products (AGEs), measured by skin autofluorescence, predict mortality in peritoneal dialysis

Does the presence of hydronephrosis have effects on micropercutaneous nephrolithotomy?

Ejaculatory function after anastomotic urethroplasty for pelvic fracture urethral injuries